Pacific Biosciences Of California (PACB) Net Cash Flow Growth (3y) (2013 - 2026)
Pacific Biosciences Of California (PACB) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn | -9.45% |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn | 60.16% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | -85.83% |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn | 43.26% |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn | -26.30% |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | 21.48% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | -127.77% |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn | 269.22% |
| 10 | Pacific Biosciences Of California | 394.53 Mn | 157.66 Mn | 12.64 Mn | 26.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.68% |
| Mar 31, 2026 | -31.18% |
| Dec 31, 2025 | -30.41% |
| Sep 30, 2025 | 31.55% |
| Jun 30, 2025 | 67.60% |
| Mar 31, 2025 | 28.03% |
| Dec 31, 2024 | -38.20% |
| Jun 30, 2024 | 26.98% |
| Mar 31, 2024 | -28.49% |
| Dec 31, 2023 | -160.52% |
| Sep 30, 2023 | 90.06% |
| Jun 30, 2023 | -77.31% |
| Mar 31, 2023 | -9.85% |
| Dec 31, 2022 | 99.79% |
| Sep 30, 2022 | -61.41% |
| Jun 30, 2022 | -143.42% |
| Mar 31, 2022 | -53.83% |
| Dec 31, 2021 | 56.60% |
| Jun 30, 2021 | -482.21% |
| Mar 31, 2021 | 356.37% |